BCEL - Atreca, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
13.62
+0.14 (+1.04%)
As of 2:21PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close13.48
Open14.12
Bid13.69 x 900
Ask14.01 x 1400
Day's Range13.55 - 14.54
52 Week Range9.51 - 29.35
Volume165,099
Avg. Volume229,392
Market Cap382.328M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-6.36
Earnings DateMar 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Atreca Announces Participation in Two Upcoming Virtual Investor Conferences

      SOUTH SAN FRANCISCO, Calif., April 06, 2020 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique.

    • GlobeNewswire

      SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atreca, Inc. - BCEL

      NEW YORK, March 12, 2020 -- Pomerantz LLP is investigating claims on behalf of investors of Atreca, Inc. (“Atreca” or the “Company”) (NASDAQ: BCEL).   Such investors are.

    • GlobeNewswire

      Atreca Reports Fourth Quarter and Full Year 2019 Financial Results

      SOUTH SAN FRANCISCO, Calif., March 11, 2020 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated.

    • GlobeNewswire

      Atreca to Present at the Cowen and Company 40th Annual Health Care Conference

      SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique.

    • GlobeNewswire

      Atreca Announces First Patient Dosed in Phase 1b Clinical Trial of ATRC-101 in Patients with Select Solid Tumors

      Atreca, Inc. (Atreca) (BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the first patient has been dosed in a Phase 1b first-in-human clinical trial evaluating ATRC-101 in patients with select solid tumor cancers. ATRC-101, a monoclonal antibody derived from a human antibody identified in a cancer patient via Atreca’s drug discovery platform, targets a ribonucleoprotein (RNP) complex and is believed to function through Driver Antigen Engagement, a novel mechanism of action in oncology.

    • GlobeNewswire

      Atreca Announces Strategic Research Collaboration with Merck to Identify Novel Antibody Targets in Oncology

      Atreca, Inc. (Atreca) (BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it has entered into a strategic research collaboration with Merck (known as MSD outside the United States and Canada), to identify the antigenic targets of select antibodies discovered by Atreca with potential utility in oncology. “We are excited to collaborate with Merck, a global leader in oncology, to identify novel antibody targets that may hold the potential to transform the future treatment of cancer,” said John Orwin, Chief Executive Officer.

    • American City Business Journals

      These new Bay Area stocks from 2019 are 'underwater' as year ends

      One third of this year's Bay Area companies that went public in the past 12 months entered trading on the day after Christmas below their original offering prices.

    • Hedge Funds Staying Clear Of Atreca, Inc. (NASDAQ:BCEL)
      Insider Monkey

      Hedge Funds Staying Clear Of Atreca, Inc. (NASDAQ:BCEL)

      We can judge whether Atreca, Inc. (NASDAQ:BCEL) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. […]

    • GlobeNewswire

      Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101

      Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application. Atreca expects to initiate a first-in-human Phase 1b clinical trial of ATRC-101 in patients with solid tumors in early 2020.

    • GlobeNewswire

      Atreca to Present at Two Upcoming Investor Conferences

      REDWOOD CITY, Calif., Nov. 14, 2019 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of.

    • GlobeNewswire

      Atreca Reports Third Quarter 2019 Financial Results and Recent Corporate Developments

      REDWOOD CITY, Calif., Nov. 12, 2019 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of.

    • GlobeNewswire

      Atreca to Highlight ATRC-101 Preclinical Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

      REDWOOD CITY, Calif., Nov. 05, 2019 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of.

    • Do Institutions Own Shares In Atreca, Inc. (NASDAQ:BCEL)?
      Simply Wall St.

      Do Institutions Own Shares In Atreca, Inc. (NASDAQ:BCEL)?

      Every investor in Atreca, Inc. (NASDAQ:BCEL) should be aware of the most powerful shareholder groups. Institutions...

    • GlobeNewswire

      Atreca Announces Appointment of Dr. Lindsey Rolfe to its Board of Directors

      Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the appointment of Lindsey Rolfe, BSc, MB ChB, MRCP, FFPM, to the company’s Board of Directors. In addition, Lawrence Steinman, M.D., Stanford University Professor and co-founder of Atreca, has resigned from the Board, effective as of August 22, 2019, but will continue to serve as a technical advisor to the company. “As we prepare to submit an Investigational New Drug (IND) application for ATRC-101 later this year and enter the clinic in early 2020, Lindsey’s deep oncology expertise and her experience in the development of oncology therapeutics will be critical as the company continues to evolve,” said John Orwin, Chief Executive Officer.

    • GlobeNewswire

      Atreca Reports Second Quarter 2019 Financial Results and Recent Corporate Developments

      REDWOOD CITY, Calif., Aug. 13, 2019 -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of.

    • Benzinga

      Stifel: Atreca Offers Attractive Oncology Drug Development Play

      Atreca has a highly differentiated approach to antibody drug discovery that moves completely away from the biologically or genetically derived hypotheses that are traditionally used to inform target selection, Willey said in a Monday initiation note.

    • GlobeNewswire

      Atreca Further Strengthens Management Team with Appointment of Lisa Decker as Chief Business Officer and Courtney Phillips as General Counsel

      Atreca, Inc. (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, today announced the appointment of Lisa L. Decker, Ph.D., as Chief Business Officer and Courtney J. Phillips as General Counsel. As Chief Business Officer, Dr. Decker will lead Atreca’s corporate development function, including its strategic partnering initiatives and alliance management.

    • Benzinga

      Atreca Opens For Trade

      Atreca, Inc. (NASDAQ: BCEL ) shares opened for trade Thursday morning at $19.90. The IPO of 7.35 million shares was priced at $17. Atreca is a biopharma company that uses its platform to discover and develop ...

    • GlobeNewswire

      Atreca Announces Pricing of Initial Public Offering

      REDWOOD CITY, Calif., June 19, 2019 -- Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel.

    • Benzinga

      Atreca IPO: What You Need To Know

      Cancer biotechs are the hottest among drug development companies, given the lucrative market opportunity before them. One such company is testing the IPO waters this week. The IPO Terms Redwood, California-based ...

    • Benzinga

      IPO Outlook For The Week: Biotechs And A Grocery Outlet

      For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Stoke Therapeutics, Inc. (STOK) will issue 6.7 million shares between ...